Cargando…

Specific viral RNA drives the SARS CoV-2 nucleocapsid to phase separate

A mechanistic understanding of the SARS-CoV-2 viral replication cycle is essential to develop new therapies for the COVID-19 global health crisis. In this study, we show that the SARS-CoV-2 nucleocapsid protein (N-protein) undergoes liquid-liquid phase separation (LLPS) with the viral genome, and pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Iserman, Christiane, Roden, Christine, Boerneke, Mark, Sealfon, Rachel, McLaughlin, Grace, Jungreis, Irwin, Park, Chris, Boppana, Avinash, Fritch, Ethan, Hou, Yixuan J., Theesfeld, Chandra, Troyanskaya, Olga G, Baric, Ralph S., Sheahan, Timothy P., Weeks, Kevin, Gladfelter, Amy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310621/
https://www.ncbi.nlm.nih.gov/pubmed/32587965
http://dx.doi.org/10.1101/2020.06.11.147199
Descripción
Sumario:A mechanistic understanding of the SARS-CoV-2 viral replication cycle is essential to develop new therapies for the COVID-19 global health crisis. In this study, we show that the SARS-CoV-2 nucleocapsid protein (N-protein) undergoes liquid-liquid phase separation (LLPS) with the viral genome, and propose a model of viral packaging through LLPS. N-protein condenses with specific RNA sequences in the first 1000 nts (5’-End) under physiological conditions and is enhanced at human upper airway temperatures. N-protein condensates exclude non-packaged RNA sequences. We comprehensively map sites bound by N-protein in the 5’-End and find preferences for single-stranded RNA flanked by stable structured elements. Liquid-like N-protein condensates form in mammalian cells in a concentration-dependent manner and can be altered by small molecules. Condensation of N-protein is sequence and structure specific, sensitive to human body temperature, and manipulatable with small molecules thus presenting screenable processes for identifying antiviral compounds effective against SARS-CoV-2.